The vaccine, jointly developed by the National Institute of Virology-Pune and Hyderabad-based Bharat Biotech International Limited (BBIL) in collaboration with the Indian Council of Medical ...
According to sources, in the minutes of the meeting of Subject Expert Committee (SEC) held on March 30, 2024, the firm presented Phase I clinical trial report with 28 days safety results along ...
Hyderabad, Feb. 24 (PTI): COVID-19 vaccine Covaxin maker Bharat Biotech International Limited is in the process of bringing out a vaccine against tuberculosis and soon the firm will sign a MoU ...
As part of the Phase II/III trial, the two-dose Covaxin was administered with 28 days apart. Bharat Biotech, which completed the Phase 2/3 trials of COVID-19 vaccine Covaxin for use in children ...
Chairman and Managing Director of Bharat Biotech International Ltd. The state has a robust transportation network and a well-established healthcare system. Kerala had set an example for other ...